| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. [PubChem] |
| Indication |
For the treatment of urinary tract infection |
| Pharmacology |
Norfloxacin is a quinolone/fluoroquinolone antibiotic. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. |
| Affected Organisms |
| • |
Enteric bacteria and other eubacteria |
|
| Biotransformation |
Via liver and kidney |
| Absorption |
Rapid |
| Half Life |
3-4 hours |
| Protein Binding |
10 and 15% (Serum protein binding) |
| Elimination |
Norfloxacin is eliminated through metabolism, biliary excretion, and renal excretion.
Renal excretion occurs by both glomerular filtration and tubular secretion as evidenced by the high rate of renal clearance (approximately 275 mL/min). |
| References |
| • |
Goldstein EJ: Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity. Am J Med. 1987 Jun 26;82(6B):3-17.
[Pubmed]
|
|
| External Links |
|